CellNetix pathologists have extensive experience with the performance and interpretation of immunohistochemical testing, and our lead IHC pathologist is fellowship-trained in immunohistochemistry. IHC is a laboratory technique that has dramatically improved the ability of pathologists to diagnose and subclassify benign and malignant neoplasms. It is useful or essential in the diagnosis, classification, and determination of prognosis for many diseases, including the classification of undifferentiated or poorly differentiated neoplasms. IHC techniques allow the distinction with a high degree of certainty between poorly differentiated carcinomas, lymphomas, sarcomas, and melanomas, as well as carcinomas of unknown primary site (determination of primary site of origin in metastases), classification of lymphomas and sarcomas, identification of infectious micro-organisms such as Herpes virus, cytomegalovirus, HHV-8, Helicobacter pylori, etc., prognostic and therapeutic marker studies such as estrogen/progesterone and Her2/neu in breast cancer, and determination of possible therapeutic response for targeted chemotherapy.